本页面由Tiger Trade Technology Pte. Ltd.提供服务

Iovance Biotherapeutics, Inc.

2.19
-0.0650-2.89%
成交量:130.11万
成交额:286.97万
市值:8.67亿
市盈率:-1.82
高:2.23
开:2.23
低:2.18
收:2.25
52周最高:8.90
52周最低:1.64
股本:3.97亿
流通股本:3.04亿
量比:0.84
换手率:0.43%
股息:- -
股息率:- -
每股收益(TTM):-1.1987
每股收益(LYR):-1.2839
净资产收益率:-53.89%
总资产收益率:-27.12%
市净率:1.24
市盈率(LYR):-1.70

数据加载中...

公司资料

公司名字:
Iovance Biotherapeutics, Inc.
交易所:
NASDAQ
成立时间:
2007
员工人数:
838
公司地址:
825 Industrial Road,Suite 100,San Carlos,California,United States
邮编:
94070
电话:
传真:
- -
简介:
Iovance Biotherapeutics, Inc.是一家新兴的生物技术公司,专注于培养细胞,使用自体肿瘤浸润淋巴细胞(TIL)治疗转移性黑色素瘤等实体瘤的细胞治疗方法的发展和商业化。该公司于2007年9月17日在内华达州成立。

董事

名称
职位
Frederick G. Vogt
Interim Chief Executive Officer and President, General Counsel; Director
Iain Dukes
Chairman of the Board
Athena Countouriotis
Director
Michael Weiser
Director
Ryan D. Maynard
Director
Wayne P. Rothbaum
Director
Wendy L. Yarno
Director

股东

名称
职位
Frederick G. Vogt
Interim Chief Executive Officer and President, General Counsel; Director
Igor P. Bilinsky
Chief Operating Officer
Corleen Roche
Chief Financial Officer and Principal Accounting Officer
Daniel Gordon Kirby
Chief Commercial Officer
Friedrich Graf Finckenstein
Chief Medical Officer
Raj K. Puri
Chief Regulatory Officer